Skip to main content

Branded

  • Vytorin helps reduce cardiac events in chronic kidney disease patients

    DENVER A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes and cardiac death in patients with chronic kidney disease, according to results of a new study.

     

    Merck said results of a 9,000-patient clinical study showed that Vytorin (ezetimibe and simvastatin) reduced the risks by 16.1% compared with placebo. Results of the study were presented Saturday at the annual meeting of the American Society of Nephrology.

     

     

  • FDA asks Xanodyne to pull painkillers from market

    SILVER SPRING, Md. A drug maker will pull a common prescription painkiller from the market following the release of clinical data that it could cause heart problems.

     

  • Deadline for Pfizer's tender offer for King extended

    NEW YORK Pfizer has extended the deadline of its $3.6 billion offer to buy King Pharmaceuticals, Pfizer said Monday.

     

    Pfizer said it had extended its tender offer to Dec. 17 because certain conditions had not been met, but the two companies plan to have it finished by the end of this year or the beginning of next year.

     

     

    King, based in Bristol, Tenn., specializes in branded opioid prescription painkillers.

     

  • OcuSoft's Zytaze now available at chain drug stores

    RICHMOND, Texas Drug maker OcuSoft has launched a prescription supplement designed to enhance botulinum toxin injections, the company said.

     

    OcuSoft announced the availability of Zytaze in several chain drug stores around the country.

     

     

    The drug is designed to extend the duration of botulinum toxin treatments, such as Allergan’s Botox (onabotulinumtoxinA), and reports have indicated that it extends them by almost 25%.

     

  • Amgen's Xgeva receives FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.

     

    The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.

     

     

  • Byetta may cut cardiovascular risk for diabetes patients

    CHICAGO — A Type 2 diabetes drug marketed by Eli Lilly and Amylin Pharmaceuticals may lower the risk of cardiovascular disease compared with other diabetes treatments, the two companies said Wednesday.

     

    According to a study presented at the American Heart Association’s scientific sessions in Chicago, use of Byetta (exenatide) was associated with a lower incidence of cardiovascular disease than insulin and several other drug classes.

     

     

  • FDA advisory committee recommends expanded use of Gardasil

    WHITEHOUSE STATION, N.J. — A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for genital warts.

    Merck announced Wednesday that the FDA Vaccines and Related Biological Products Advisory Committee recommended approval of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for males and females ages 9 to 26 years to prevent anal cancer and anal intraepithelial neoplasia, both diseases that result from infection by the human papillomavirus.

  • Generic versions of Alimta, Abilify get shut down by district courts

    INDIANAPOLIS — The U.S. District Court for the District of Delaware has upheld a patent held by Indianapolis-based drug maker Eli Lilly covering a chemotherapy drug, Lilly said Monday.

     

    The case concerns a patent covering Alimta (pemetrexed) that expires in July 2016 and generic drug maker Teva Pharmaceutical Industries’ challenge to it.

     

     

X
This ad will auto-close in 10 seconds